<DOC>
	<DOCNO>NCT01227564</DOCNO>
	<brief_summary>This study individual early Alzheimer 's disease design ass : ( 1 ) safety tolerability ( 2 ) capacity ACC-001 QS-21 adjuvant reduce brain amyloid load measure positron emission tomography ( PET ) scan .</brief_summary>
	<brief_title>Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Concern change cognition express subject informant know subject well MiniMental State Examination ( MMSE ) score â‰¥ 25 Global Clinical Dementia Rating = 0.5 . General cognition functional performance sufficiently preserve diagnosis Alzheimer 's dementia make site physician time screen . Amyloid burden detect screen brain PET scan . Other inclusion criterion apply . Significant neurological disease early Alzheimer 's disease Major psychiatric disorder symptom Contraindication undergo brain MRI Unstable medical condition Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Early Alzheimer 's disease</keyword>
	<keyword>active immunization</keyword>
	<keyword>amyloid imaging</keyword>
</DOC>